RELMADA THERAPEUTICS, INC. — Director's Dealing 2021

Jan 11, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RELMADA THERAPEUTICS, INC. (RLMD)
CIK: 0001553643
Period of Report: 2021-01-07

Reporting Person: TRAVERSA SERGIO (Director, CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-07	Options to purchase common stock	$33.43	A	250000	Acquired	2031-01-07	Common Stock (250000)	Direct
2021-01-07	Options to purchase common stock	$33.43	A	250000	Acquired	2031-01-07	Common Stock (250000)	Direct

Footnotes

F1: The options vest from the date of grant in equal quarterly increments of 6.25% over a four-year period.

F2: The options vest 25% one year from the date of grant, and thereafter in equal quarterly increments of 6.25% over the following three years. The options are subject to forfeiture upon failure by the Issuer to reach certain corporate objectives in 2021.